Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McGill University

$210,000.00

Using Large-Scale Genetic Databases to Identify New Therapeutic Targets for Chronic Kidney Disease

FY 2024-25

Summary
In Canada, chronic kidney disease causes $32 billion per year in health care costs, substantially reduces the quality of life, and results in early mortality, as it is the 10th leading cause of death. The term chronic kidney disease refers to a persistent impairment in the filtering function of the kidney. This disease can progress to end-stage kidney disease, which is fatal without dialysis or a kidney transplant, the only available treatment options. End-stage kidney disease is irreversible, highlighting the need to develop new preventive therapies to treate chronic kidney disease before it progresses. Developing a new drug costs one to two billion dollars. This cost is largely due to the high failure rate of drugs to deliver a therapeutic benefit. Tens of millions of dollars are invested in the development of a medicine only to find out too late that the drug does not have the desired effect. Identifying a therapeutic target is notoriously difficult in the case of kidney disease because there is no animal model that fully recapitulates the disease observed in humans. We therefore need an innovative way of finding therapeutic targets. Recent studies have shown that drugs supported by genetic evidence are more than twice as likely to be effective. Twin studies have shown that 55% of the risk of chronic kidney disease is explained by our genetic differences. In this project, we will characterize the genetic variants that cause chronic kidney disease to find new treatments. We will test the expression of 20,000 genes in 53 human tissues and the concentrations of 4,670 circulating proteins. This large-scale profiling will enable us to prioritise the most effective and safest therapeutic targets for chronic kidney disease. This project could significantly advance our understanding of chronic kidney disease. It could accelerate the development of drugs for chronic kidney disease, improving quality of life and reducing health care costs for all Canadians.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
513835
Name
Gagnon Éloi
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Using Large-Scale Genetic Databases to Identify New Therapeutic Targets for Chronic Kidney Disease
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$210,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Chronic Kidney Disease; Human Genetics; Mendelian Randomization; Therapeutic Targets
Abstract
In Canada, chronic kidney disease causes $32 billion per year in health care costs, substantially reduces the quality of life, and results in early mortality, as it is the 10th leading cause of death. The term chronic kidney disease refers to a persistent impairment in the filtering function of the kidney. This disease can progress to end-stage kidney disease, which is fatal without dialysis or a kidney transplant, the only available treatment options. End-stage kidney disease is irreversible, highlighting the need to develop new preventive therapies to treate chronic kidney disease before it progresses. Developing a new drug costs one to two billion dollars. This cost is largely due to the high failure rate of drugs to deliver a therapeutic benefit. Tens of millions of dollars are invested in the development of a medicine only to find out too late that the drug does not have the desired effect. Identifying a therapeutic target is notoriously difficult in the case of kidney disease because there is no animal model that fully recapitulates the disease observed in humans. We therefore need an innovative way of finding therapeutic targets. Recent studies have shown that drugs supported by genetic evidence are more than twice as likely to be effective. Twin studies have shown that 55% of the risk of chronic kidney disease is explained by our genetic differences. In this project, we will characterize the genetic variants that cause chronic kidney disease to find new treatments. We will test the expression of 20,000 genes in 53 human tissues and the concentrations of 4,670 circulating proteins. This large-scale profiling will enable us to prioritise the most effective and safest therapeutic targets for chronic kidney disease. This project could significantly advance our understanding of chronic kidney disease. It could accelerate the development of drugs for chronic kidney disease, improving quality of life and reducing health care costs for all Canadians.
Competitiondate
202410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gagnon, Éloi
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $210,000~ $0~
McGill University - $210,000 Grant (2024-25) | Canada Spends